Replies to post #15157 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I suspect that for all intents and purposes all [non-ATryn] programs are already stopped.<

This is evident from the slippage in the timelines of the non-ATryn programs and the fact that GTC has not paid its 50% share of the modest development expenses in the LFB joint venture.